Bookbuilding IPO | ₹[.] Cr | Listing at BSE, NSE
Gaudium IVF IPO is a book build issue of 2.09 crore shares. The issue is a combination of fresh issue of 1.14 crore shares and offer for sale of 0.95 crore shares.
Gaudium IVF IPO opens for subscription on Feb 20, 2026 and closes on Feb 24, 2026. The allotment for the Gaudium IVF IPO is expected to be finalized on Feb 25, 2026. Gaudium IVF IPO will list on BSE, NSE with a tentative listing date fixed as Feb 27, 2026.
Gaudium IVF IPO price band is set at [.] to [.] per share.
Sarthi Capital Advisors Pvt.Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Refer to Gaudium IVF IPO RHP for detailed Information.
IPO Open
Fri, Feb 20, 2026
IPO Close
Tue, Feb 24, 2026
Price Band
To be declared
Market Cap (Pre-IPO)
To be declared
| IPO Date | 20 to 24 Feb, 2026 |
| Listing Date | Fri, Feb 27, 2026T |
| Face Value | ₹5 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh Capital & OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,08,86,200 shares (agg. up to ₹[.] Cr) |
| Fresh Issue | 1,13,92,500 shares (agg. up to ₹[.] Cr) |
| Offer for Sale | 94,93,700 shares of ₹5 (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 6,13,94,384 shares |
| Share Holding Post Issue | 7,27,86,884 shares |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII Shares Offered | Not less than 15.00% of the Net Issue |
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India and have expanded into several states utilizing a hub-and-spoke model.
The company operates over thirty locations, which include seven hubs (centres) and twenty-eight spokes. The organization has entered into a strategic alliance with Infertility Experts, known as Spokes, to achieve the mutual objective of raising awareness regarding Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) treatments.
The company serves patients from various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company has centres in major cities: two in Delhi (Janakpuri, Kailash Colony), and one each in Mumbai (Khar West), Ludhiana, Srinagar, Patna, and Bangalore, covering key locations across India.
The company offers specialized fertility services, including In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), and ovulation induction. Our treatments are designed for various infertility challenges for both genders. We also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis, as well as high-risk pregnancy management for women with complex fertility histories or health conditions.
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 106.62 | 88.51 | 51.01 | 36.63 |
| Total Income | 49.75 | 70.96 | 48.15 | 44.26 |
| Profit After Tax | 12.51 | 19.13 | 10.32 | 13.53 |
| EBITDA | 18.95 | 28.63 | 19.27 | 20.07 |
| NET Worth | 58.85 | 46.30 | 26.99 | 22.73 |
| Reserves and Surplus | 28.16 | 15.60 | 26.00 | 21.74 |
| Total Borrowing | 22.51 | 18.93 | 15.73 | 9.78 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure towards establishment of New IVF Centers of the Company. | 50.00 |
| 2 | Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company. | 20.00 |
| 3 | General Corporate Purpose | |
| Total | 70.00 |
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 21.25% | 41.31% |
| ROCE | 21.03% | 39.70% |
| Debt/Equity | 0.38 | 0.41 |
| RoNW | 21.34% | 41.71% |
| PAT Margin | 25.14% | 26.96% |
| EBITDA Margin | 38.29% | 40.48% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 3.12 | 3.44 |
| Promoter Holding | 99.98% |
Lead Manager Reports
Gaudium IVF IPO is a main-board IPO of 2,08,86,200 equity shares of the face value of ₹5 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The IPO opens on Fri, Feb 20, 2026, and closes on Tue, Feb 24, 2026.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Gaudium IVF IPO using UPI as a payment gateway. Zerodha customers can apply in Gaudium IVF IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Gaudium IVF IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Gaudium IVF IPO opens on Fri, Feb 20, 2026 and closes on Tue, Feb 24, 2026.
Gaudium IVF IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Gaudium IVF IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Gaudium IVF IPO will be done on Wednesday, February 25, 2026, and the allotted shares will be credited to your demat account by Thu, Feb 26, 2026. Check the Gaudium IVF IPO allotment status.
The Gaudium IVF IPO listing date is not yet announced. The tentative date of listing is Fri, Feb 27, 2026.
